Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, resp... by Fei Wang, Yongjiu Wang, Bin Xiong, Zhenlin Yang, Jingfen Wang, Yumin Yao, Lixiang Yu, Qinye Fu, Liang Li, Qiang Zhang, Chao Zheng, Shuya Huang, Liyuan Liu, Chun Liu, Huaibo Sun, Beibei Mao, Dong-Xu Liu, Zhigang Yu

Get full text

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 tri... by Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu

Get full text

Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial by Jianli Ma, Jingxuan Wang, Ting Xu, Quchang Ouyang, Xiaojia Wang, Jingfen Wang, Lu Gan, Zhong Ouyang, Daren Lin, Tao Sun, Changping Shan, Herui Yao, Baochun Zhang, Zhengguang Li, Zhixiang Zhuang, Ying Lu, Hongwei Yang, Jian Huang, Xingwang Yang, Hongmei Sun, Qingyuan Zhang

Get full text

Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis by Jiayu Wang, Qingyuan Zhang, Huiping Li, Zhongsheng Tong, Quchang Ouyang, Huihui Li, Yuee Teng, Biyun Wang, Tao Sun, Jingfen Wang, Wei Li, Zhaofeng Niu, Hongsheng Li, Chang Gong, Shu Wang, Xinshuai Wang, Xinhong Wu, Ning Liu, Guohua Yu, Fei Liu, Xianghui Duan, Shuya Wang, Yaping Meng, Li Wang, Binghe Xu

Get full text

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort by Xichun Hu, Qingyuan Zhang, Tao Sun, Huihua Xiong, Wei Li, Yuee Teng, Yen-Shen Lu, Ling-Ming Tseng, Min Yan, Hongsheng Li, Danmei Pang, Shin-Cheh -Chen, Wenyan Chen, Ou Jiang, Jingfen Wang, Xinhong Wu, Xian Wang, Aimin Zang, Xiaojia Wang, Julie M. Collins, Ethan Fan, Lin Jiang, Xiaoling Zeng, Nicholas C. Turner

Get full text

A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors by Mingchuan Zhao, Xichun Hu, Pengpeng Zhuang, Aiping Zeng, Yan Yu, Zhendong Chen, Hongmei Sun, Weihua Yang, Lili Sheng, Peijian Peng, Jingfen Wang, Tienan Yi, Minghong Bi, Huaqiu Shi, Mingli Ni, Xiumei Dai, Changlu Hu, Hongjie Xu, Dongqing Lv, Qingshan Li, Kaijian Lei, Xia Yuan, Ou Jiang, Xicheng Wang, Baihui Hu, Zhe Hou, Zhaoping Su, Song Zheng, Ming Zhou, Changlin Dou

Get full text

8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical... by Biyun Wang, Xiuchun Chen, Hongtao Li, Jing Sun, Xinjian Jia, Tao Sun, Yumin Yao, Jingfen Wang, Jincheng Li, Xujuan Wang, Xiaojia Wang, Cuizhi Geng, Yu Ren, Liuzhong Yang, Jun Jia, Yiding Chen, Zhihua Li, Yunhui Huang, Baojiang Li, Guosheng Ren, Jian Chen, Shiyou Yu, Jiazhuan Mei, Zhidong Pei, Caixia Liu, Xuchen Cao, Chao Deng, Mingde Huang, Yueyin Pan, Yi Tu, Zhiye Zhang, Ruizhen Luo, Peipei Wang, Jingming Dong, Honghuan Zhao, Song Lu, Chaolong Zhu, Shaona Cai, Shuhai Wang, Xichun Hu

Get full text